ClinicalTrials.gg
RecruitingNCT07154745Updated Aug 5, 2026

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

A Phase 3 interventional study of Pozelimab and Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Recruiting at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.

Started
2026
with 1 other
Phase 3
5 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2026, is one of 5 in phase 3, and was the 9th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH).

The aim of the study is to see how well the pozelimab and cemdisiran combination works to lower hemolysis in participants whose PNH has been not well controlled even after taking other complement component 5 (C5) inhibitors, eculizumab/eculizumab biosimilar, ravulizumab or crovalimab.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drugs?
  • How much of the study drugs are in the blood at different times?
  • Whether the body makes antibodies against the study drug (which could make the study drugs not work as well or could lead to side effects)
Read the detailed description

The treatment period has two parts, a Treatment Period (TP, 28 weeks) and an Extension treatment Period (EP, 52 weeks).

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of PNH confirmed by a history of high-sensitivity flow cytometry from prior testing
  2. Currently treated with marketed eculizumab, ravulizumab, or crovalimab at the labeled dose for at least 6 months
  3. LDH persistently > 1.5 × (ULN) in the previous 6 months that the Principal Investigator (PI) attributes is due to intravascular hemolysis
  4. At least 2 screening LDH values from different visits as described in the protocol
  5. Willing and able to comply with clinic/remote visits and study-related procedures, including completion of the full series of meningococcal vaccinations required per protocol and agreement to continue to remain up to date with these vaccinations during the study

Key Exclusion Criteria:

  1. Receipt of an organ transplant, history of bone marrow transplantation or other hematologic transplants
  2. Body weight \<40 kilograms at screening visit
  3. Patients with a known or suspected C5 mutation that is to their current C5i treatment as described in the protocol
  4. Any active or ongoing infection within 2 weeks of screening or during the screening period or any recent infection as described in the protocol
  5. Known hereditary complement deficiency

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Pozelimab + Cemdisiran Combo

    Drug: Pozelimab · Drug: Cemdisiran

Interventions

  • Administered per the protocol

    Also known as: REGN3918

  • Administered per the protocol

    Also known as: ALN-CC5

06

What researchers measure

Primary outcomes

  1. Percent change in Lactate Dehydrogenase (LDH) during TP

    Time frame: From baseline to week 28

Secondary outcomes

  1. Normalization of LDH

    Time frame: Through week 52

  2. Adequate control of hemolysis (LDH ≤1.5 × ULN)

    Time frame: Through week 52

  3. Transfusion avoidance

    Not requiring a Red Blood Cell (RBC) transfusion as per protocol algorithm based on hemoglobin values

    Time frame: Through week 52

  4. Hemoglobin stabilization

    Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level of ≥2 g/dL

    Time frame: Through week 52

  5. Change in hemoglobin from baseline

    Time frame: Through week 52

  6. Change in fatigue

    As measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. The FACIT-Fatigue assesses the level of fatigue using a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating a higher quality of life

    Time frame: Through week 52

  7. Occurrence of all Adverse Events (AEs)

    Time frame: Through week 52

  8. Severity of all AEs

    Time frame: Through week 52

  9. Occurrence of all Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Through week 52

  10. Severity of all TEAEs

    Time frame: Through week 52

  11. Change from baseline in Total Complement Hemolytic Activity Assay (CH50)

    Time frame: Through week 52

  12. Concentrations of total pozelimab

    Time frame: Through week 52

  13. Concentrations of cemdisiran

    Time frame: Through week 52

  14. Concentrations of total C5

    Time frame: Through week 52

  15. Incidence of Anti-Drug Antibody (ADA) to pozelimab

    Time frame: Through week 52

  16. Magnitude of ADA to pozelimab

    Time frame: Through week 52

  17. Incidence of ADA to cemdisiran

    Time frame: Through week 52

  18. Magnitude of ADA to cemdisiran

    Time frame: Through week 52

  19. Percent change in LDH during EP

    Time frame: From baseline to week 24 and week 52

07

Study locations

20 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2030, 43 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's planned 43 months is above that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Sep 4, 2025
StartActual
Jun 11, 2026
Primary completionEst.
Jan 18, 2030
CompletionEst.
Dec 4, 2031
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154745
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Jun 11, 2026
Primary completion
Jan 18, 2030 (estimated)
Completion
Dec 4, 2031 (estimated)
Last update
Aug 5, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pozelimab · Cemdisiran

Start the discussion